| Market Cap | 281.12M |
| Revenue (ttm) | 46.08M |
| Net Income (ttm) | 5.34M |
| Shares Out | 40.54M |
| EPS (ttm) | 0.11 |
| PE Ratio | 52.60 |
| Forward PE | 39.51 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 72,367 |
| Open | 15.22 |
| Previous Close | 14.99 |
| Day's Range | 14.94 - 15.61 |
| 52-Week Range | 7.06 - 15.61 |
| Beta | 0.33 |
| Analysts | Strong Buy |
| Price Target | 18.00 (+18.42%) |
| Earnings Date | Aug 13, 2025 |
About BWAY
BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States, East Asia, and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer’s disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson’s diseases. The company serves do... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 2 analysts, the average rating for BWAY stock is "Strong Buy." The 12-month stock price target is $18.0, which is an increase of 18.42% from the latest price.
News
BrainsWay Targets Expansion of its Total Addressable Market through a Strategic Investment in Neuromodulation Systems Developer, Neurolief Ltd.
This investment marks BrainsWay's entrance into the market for mental health therapies that can be administered outside of a clinic, including at home
BrainsWay Acquires Minority-Stake in Axis Integrated Mental Health
The Investment is part of BrainsWay's ongoing strategy to acquire minority positions in leading U.S. mental health providers to help them raise awareness for and expand access to transformative care T...
BrainsWay Ltd. (BWAY) Q2 2025 Earnings Call Transcript
BrainsWay Ltd. (NASDAQ:BWAY) Q2 2025 Earnings Conference Call August 13, 2025 8:30 AM ET Company Participants Hadar Levy - Chief Executive Officer Ido Marom - Chief Financial Officer Conference Call ...
BrainsWay Reports Second Quarter 2025 Financial Results and Operational Highlights
Achieved record quarterly revenue of $12.6 million in Q2 2025, an increase of 26% compared to Q2 2024 Operating profit totaled $0.6 million and Adjusted EBITDA rose to $1.5 million, Raised full-year 2...
BrainsWay Reports Positive Results from Multicenter Randomized Study of Accelerated Deep TMS for Major Depressive Disorder (MDD)
Improvement in depression scores, response and remission were all found to be comparable with standard Deep TMS in non-inferiority trial Improvement in depression scores, response and remission were a...
BrainsWay Announces Gold Sponsorship at the 2025 Clinical TMS Society Annual Meeting in San Diego
BURLINGTON, Mass. and JERUSALEM, June 10, 2025 (GLOBE NEWSWIRE) -- BrainsWay Ltd.
BrainsWay Announces $5 Million Minority-Stake Investment in Stella MSO, LLC
BrainsWay is actively evaluating similar investments in other leading U.S. mental health providers to raise awareness and expand access to transformative care BrainsWay is actively evaluating similar ...
BrainsWay Ltd. (BWAY) Q1 2025 Earnings Call Transcript
BrainsWay Ltd. (NASDAQ:BWAY) Q1 2025 Earnings Conference Call May 13, 2025 8:30 AM ET Company Participants Brian Ritchie – LifeSci Advisors LLC Hadar Levy – Chief Executive Officer Ido Marom – Chief ...
BrainsWay Reports First Quarter 2025 Financial Results and Operational Highlights
Achieved r ecord quarterly s ales of $11. 5 million in Q 1 202 5 , an increase of 27% compared to Q 1 202 4
BrainsWay Ltd. (BWAY) Q4 2024 Earnings Call Transcript
BrainsWay Ltd. (NASDAQ:BWAY) Q4 2024 Earnings Conference Call March 11, 2025 8:30 AM ET Company Participants Brian Ritchie - Investor Relations, LifeSci Advisors Hadar Levy - Chief Executive Officer ...
BrainsWay Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Highlights
Achieved r ecord quarterly s ales of $11.4 million in Q4 2024 , an increase of 27% compared with Q4 2023
BrainsWay Reports Positive Independent Pilot Data on Accelerated Deep TMS Treatment of Alcohol Use Disorder
BURLINGTON, Mass. and JERUSALEM, Dec. 12, 2024 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in the advanced non-invasive treatment of brain ...
BrainsWay Reports Promising Feasibility Data Showing Pain Reduction with Deep TMS Therapy
BURLINGTON, Mass. and JERUSALEM, Israel, Nov. 20, 2024 (GLOBE NEWSWIRE) -- BrainsWay Ltd.
BrainsWay Ltd. (BWAY) Q3 2024 Earnings Call Transcript
BrainsWay Ltd. (NASDAQ:BWAY) Q3 2024 Earnings Conference Call November 12, 2024 8:30 AM ET Company Participants Brian Ritchie - IR, LifeSci Advisors Hadar Levy - CEO Ido Marom - CFO Conference Call P...
BrainsWay Reports Third Quarter 2024 Financial Results and Operational Highlights
Robust 26% Year-over-Year Revenue Growth in Q3 2024 Raising Full-Year 2024 Revenue Guidance to $40-41 Million and Initiating Profitability Guidance Conference Call to be Held Today at 8:30 AM ET BURLI...
BrainsWay to Report Third Quarter 2024 Financial Results On November 12, 2024
BURLINGTON, Mass. and JERUSALEM, Oct. 29, 2024 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatme...
BrainsWay Further Penetrates East Asia with Placement of 15 Additional Deep TMS™ Systems in Taiwan and South Korea
BURLINGTON, Mass. and JERUSALEM, Israel, Oct. 09, 2024 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation...
BrainsWay Announces US$20 Million Private Placement with Valor Equity Partners
Company to leverage capital and Valor's expertise for strategic initiatives building market awareness, R&D roadmap, data analysis capabilities, and expanding access to Deep TMS™
BrainsWay Announces Significant Expansion on U.S. East Coast
BURLINGTON, Mass. and JERUSALEM, Sept.
Israel Ministry of Defense Clears BrainsWay Deep TMS™ for PTSD Reimbursement at Israeli Hospitals
BURLINGTON, Mass. and JERUSALEM, Israel, Sept. 10, 2024 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulatio...
BrainsWay Appoints Richard A. Bermudes, M.D.
Dr. Bermudes is Widely Considered One of the Preeminent U.S. Clinicians in the TMS Field Dr. Bermudes is Widely Considered One of the Preeminent U.S. Clinicians in the TMS Field
BrainsWay: Operating Leverage Driving Upside
BrainsWay reported strong earnings in Q2, with growth remaining strong and margins continuing to improve. Growth among enterprise accounts and internationally should ensure BrainsWay continues to perf...
BrainsWay Ltd. (BWAY) Q2 2024 Earnings Call Transcript
BrainsWay Ltd. (NASDAQ:BWAY) Q2 2024 Earnings Call Transcript August 6, 2024 8:30 AM ET Company Participants Brian Ritchie - IR, LifeSci Advisors Hadar Levy - CEO Ido Marom - CFO Conference Call Part...
BrainsWay Reports Second Quarter 2024 Financial Results and Operational Highlights
Generated Robust 28 % Year-over-Year Revenue Growth in Q2 2024 Recorded Positive Quarterly Net Income for Third Consecutive Quarter, and Positive Adjusted EBITDA and Cash Flow from Operations for Four...
BrainsWay to Report Second Quarter 2024 Financial Results on August 6, 2024
BURLINGTON, Mass. and JERUSALEM, July 23, 2024 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatme...